Sickle Cell Disease (SCD) – Market Access and Reimbursement Insights Report – 2025

Sickle Cell Disease (SCD) Market Access and Reimbursement Insights

Thelansis’s “Sickle Cell Disease (SCD) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.

Sickle Cell Disease (SCD) Overview

Sickle cell disease (SCD) is a serious inherited blood disorder caused by a mutation in the HBB gene that produces abnormal hemoglobin S, leading red blood cells to become rigid, crescent‑shaped, and prone to blocking blood vessels, resulting in chronic hemolytic anemia, painful vaso‑occlusive crises, and multi‑organ complications such as stroke, pulmonary hypertension, kidney damage, and increased infection risk due to functional asplenia. The disease is most prevalent in sub‑Saharan Africa, India, the Middle East, and parts of the Americas, and while newborn screening and comprehensive care have improved survival in high‑income countries, children in low‑resource regions remain at high risk of early mortality.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.

*Survey and interview discussion guide are customized based on client requirements

Deliverables format:

• PowerPoint presentation

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Key business questions answered:

• Market access and reimbursement for current therapies
• Coverage on plans
• Market access restrictions
• Rebates and contracting
• Factors influencing formulary access
• HEOR requirements and influence, etc.
• Expected market access and reimbursement for key emerging therapies
• Level of awareness
• Anticipated coverage on plans
• Factors that would improve market access
• Pricing, etc.
• Impact on brand use
• Key factors driving and limiting brand use
• Best and worst performers on market access, etc.
• Evolving environment
• Payer expectations from emerging therapies
• New policies and their expected impact, etc.
• Advise to drug manufacturers and developers

Read more: Sickle Cell Disease (SCD) – Market Access and Reimbursement Insights Report – 2025